- Stronger Yuan Needed for Global Rebalancing: IMF Chief
- Washington Not Trying to Contain China: Obama
- Japan Third Quarter GDP Jumps; 2010 Growth May Slow
- Quiz: How Much Do You Know About Green?
- Citi Rejects Terra Firma's Latest Bid to Save EMI: Report
- JP Morgan to Bid Over $3 Billion for Cazenove Stake
- Analysis: APEC Nations Back Face-Saving Climate Plan
- BlackRock: Central Banks To Be Net Buyers of Gold
- GM to Start Repaying $6.7 Billion US Government Loan
- Warren Buffett to CNBC: 'I Haven't Bought American Express In Years'
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- U.S. Stocks Rally for the Second Straight Week
- Dollar is Not Plunging—So 'Calm Down': Market Strategist
- Strategists Say Markets Have More Upside — But How Much?
- Hirschhorn: Risk-Averse Traders
- Roginsky: A Funny Thing Happened on the Way to Financial Reform
- This Year's Biggest Thanksgiving Leftover: Cash
- TV Series Inks Unique Deal For Fight
- Vattenfall names Nuon chief as new CEO
- Obama prods China to accept ‘universal rights’
- Airbus parent EADS reports Q3 loss on weak dollar
- Calif. man set for hearing in wine warehouse fire
- Census: Small US cities lose luster in downturn
- Dakotas might see record sunflower yields
- Emirates chief: Boeing, Airbus orders possible
- Remittances of Filipinos abroad up 8.6 percent
- Source: GM to begin repaying aid by year-end
Text Size 
NEW YORK - Bristol-Myers Squibb Co. and Alder Biopharmaceuticals Inc. said Tuesday they signed a collaboration deal potentially worth $1 billion, with a key focus on a rheumatoid arthritis treatment.
Bristol-Myers will pay Alder $85 million upfront for ALD518, which is now past midstage development for rheumatoid arthritis, an inflammatory condition that can cause joint damage. The agreement also includes the potential for development-based and regulatory-based milestone payments of up to $764 million and sales-based milestones that could be more than $200 million.
Alder will also receive sales royalties. Meanwhile, Alder gives Bristol-Myers exclusive worldwide rights to develop and sell ALD518 for all potential indications, excluding cancer.
Bristol-Myers already sells the drug Orencia as a rheumatoid arthritis treatment. Sales rose 36 percent to $162 million during the third quarter.
Alder, based in Bothell, Wash., has an option to require New York-based Bristol-Myers Squibb to make an equity investment of up to $20 million in Alder during an initial public offering.
Print
Email
- Where, what, how.
- Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
- For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
- Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
- The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
- Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
Data is a real-time snapshot *Data is delayed at least 15 minutes